Vaccinex to Present Update on PDAC/Pepinemab Study; New ActivMAb Application - Seite 2

New ActivMAb “Antigen Virus” Application
Meeting	CHI's 20th Annual DOT Conf: Antibodies Against Membrane Proteins
Date:	September 28, 2023
Time:	8:35 a.m. ET: GPCR Sessio
Session Title:	Discovery of High-Affinity Functional Antibodies Specific for CXCR5 and Other Multi-Pass Membrane Proteins
Presenter	Ernest Smith, Ph.D., Senior Vice President, Research
	Presentation will be available here

Vaccinex will describe use of the new “Antigen Virus” application, a potential tool to improve antibody development for high complexity, hard-to-drug targets, such as G-protein coupled receptors (GPCRs) and ion channels. This technology, a powerful complement to the existing ActivMAb platform, allows the direct incorporation of properly folded, complex multi-pass membrane proteins into specially designed poxviruses. We believe based on our rigorous evaluation that the ActivMab system can readily generate functional and properly folded complex proteins that can be used for selection of novel, high value, antibody therapeutics. A new manuscript describing this technology was recently published in mAbs, a leading biotech journal.

About Pepinemab
Pepinemab is a humanized IgG4 monoclonal antibody designed to block SEMA4D, which can trigger collapse of the actin cytoskeleton and loss of homeostatic functions of astrocytes and glial cells in the brain and dendritic cells in immune tissue. Pepinemab has been administered to more than 400 patients and appears to be well-tolerated and to have a favorable safety profile.

Vaccinex has global commercial and development rights to pepinemab and is the sponsor of the NCT05102721 PDAC trial. BAVENCIO/avelumab is provided by Merck KGaA, Darmstadt, Germany, previously as part of an alliance between the healthcare business of Merck KGaA, Darmstadt, Germany and Pfizer.

About ActivMAb
ActivMAb is a proprietary mammalian cell-based antibody discovery platform developed by Vaccinex with unique capabilities for multi-pass membrane targets such as G-protein-coupled receptors (GPCRs). The ActivMAb technology has multiple applications including: complex membrane antigen presentation and expression, antibody and antigen discovery, directed evolution and protein optimization.